ArriVent Biopharma
IPO- Website
- arriventbio.com
- Total Funding
- $305.0M
- Last Round
- $150.0M Series A
- Rounds
- 2
About
ArriVent BioPharma is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines.
Summary
ArriVent Biopharma is a Healthcare company. It has raised $305.0M in total across 2 rounds. Investors include Hillhouse Capital, Sofinnova Investments and General Catalyst.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jan 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Hillhouse Capital
1 round
Sofinnova Investments
1 round
General Catalyst
1 round
OrbiMed
2 rounds
Octagon Capital Advisors
2 rounds
Lilly Asia Ventures
2 rounds
Boyu Capital
1 round
Zoo Capital
1 round
Lyra Ventures
1 round
Catalio Capital Management
1 round
HBM Healthcare Investments
1 round
Shanghai Healthcare Capital
1 round
Sequoia Capital
1 round
Similar Companies
Healthcare cost management company providing data analytics and network-based payment solutions t...
American dietary supplements company owning Nature's Bounty, Solgar, and Puritan's Pride brands; ...
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Healthcare company in Europe
Mehiläinen is a leading Finnish private healthcare company providing medical, health, and special...